Mirikizumab
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | interleukin 23A |
Clinical data | |
Synonyms | LY3074828 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6380H9842N1686O2004S48 |
Molar mass | 143.8 g/mol |
Mirikizumab (LY3074828) (INN[1]) is a human monoclonal antibody designed for the treatment of psoriasis.
This drug was developed by Eli Lilly and Co.[2] As of 2018, mirikizumab is undergoing Phase III trials.
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.